How can the U.S. cultivate a strong and competitive biosimilars market?

Biologics have revolutionized treatment for serious diseases and profoundly impacted millions of patients. Since enactment of the Biologics Price Competition and Innovation Act, the U.S. biosimilars market has made great progress. As of April 2020, the FDA has approved 26 biosimilars referencing 9 different biologics with 17 on the market, while 75 products are awaiting approval in FDA’s biosimilar program.

Extensive debate continues about biosimilar progress and what it will take to achieve a competitive U.S. healthcare market with biosimilars playing a key role.

This panel will share diverse perspectives on how the U.S. can:
• Encourage competition between biosimilars and their reference products;
• Promote accurate educational content about biosimilars and their reference products; and
• Implement regulatory standards to demonstrate biosimilarity and interchangeability, and facilitate accurate product identification.